Bill
HR 5278
The Affordable Inhalers and Nebulizers Act of 2025 ensures affordable access to essential respiratory devices through price regulation, insurance coverage, and subsidies for low-income patients.
The Affordable Inhalers and Nebulizers Act of 2025 aims to improve access to affordable inhalers and nebulizers for individuals with respiratory conditions, such as asthma and chronic obstructive pulmonary disease (COPD). The bill seeks to address the rising costs of these essential medical devices and medications, ensuring that patients can obtain the treatments they need without financial hardship.
The bill includes several important provisions designed to enhance affordability and access:
Price Regulation: The legislation proposes mechanisms to regulate the prices of inhalers and nebulizers, ensuring they are affordable for consumers.
Insurance Coverage: It mandates that health insurance plans cover inhalers and nebulizers with minimal out-of-pocket costs for patients, aiming to eliminate high co-pays and deductibles that can deter individuals from obtaining necessary treatments.
Subsidies for Low-Income Patients: The bill includes provisions for subsidies or financial assistance for low-income individuals who may struggle to afford these devices.
Increased Availability: The act encourages the production and distribution of generic inhalers and nebulizers to foster competition and lower prices in the market.
Patient Education: It promotes educational programs to inform patients about their options for inhalers and nebulizers, including how to use them effectively and the importance of adherence to prescribed therapies.
The following groups would be directly impacted by the Affordable Inhalers and Nebulizers Act:
Patients: Individuals with asthma, COPD, and other respiratory conditions would benefit from reduced costs and improved access to necessary treatments.
Healthcare Providers: Physicians and healthcare professionals would have more resources to recommend affordable treatment options to their patients.
Insurance Companies: Health insurers would need to adjust their coverage policies to comply with the new regulations set forth in the bill.
Pharmaceutical Companies: Manufacturers of inhalers and nebulizers may face new pricing regulations and increased competition from generic alternatives.
Introduced: The bill was introduced in the House of Representatives on September 10, 2025.
Committee Referral: Upon introduction, HR 5278 was referred to the Committee on Energy and Commerce, as well as the Committees on Ways and Means and Education and Workforce for further consideration. The timeline for deliberation by these committees will be determined by the Speaker of the House.
The bill is sponsored by Kweisi Mfume and has multiple cosponsors, including:
HR 5278 has a companion bill, S 2756, which is currently under consideration in the Senate, indicating bipartisan support for the initiative.
This summary provides an overview of the Affordable Inhalers and Nebulizers Act of 2025, highlighting its purpose, key provisions, affected parties, and legislative status. The bill represents a significant step toward improving healthcare accessibility for individuals with respiratory conditions.
Compiled from official sources — confirm details with the bill’s official record.
Sign in to ask a question.
